Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Identifieur interne : 002566 ( PubMed/Checkpoint ); précédent : 002565; suivant : 002567Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Auteurs : Xiliang Wang [République populaire de Chine] ; Bing Ni ; Xinan Du ; Guangyu Zhao ; Wenda Gao ; Xinfu Shi ; Songle Zhang ; Liangyan Zhang ; Dong Wang ; Deyan Luo ; Li Xing ; Haiyan Jiang ; Wanling Li ; Man Jiang ; Liwei Mao ; Yangdong He ; Yu Xiao ; Yuzhang WuSource :
- Antiviral therapy [ 1359-6535 ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (pharmacologie), Anticorps antiviraux (toxicité), Anticorps antiviraux (usage thérapeutique), Cellules Vero, Effet cytopathogène viral (), Equus caballus, Femelle, Fragments Fab d'immunoglobuline (administration et posologie), Fragments Fab d'immunoglobuline (immunologie), Fragments Fab d'immunoglobuline (toxicité), Fragments Fab d'immunoglobuline (usage thérapeutique), Immunisation passive, Injections péritoneales, Modèles animaux de maladie humaine, Relation dose-effet des médicaments, Souris, Spécificité des anticorps, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Tests de neutralisation, Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Fragments Fab d'immunoglobuline.
- immunologie : Anticorps antiviraux, Fragments Fab d'immunoglobuline, Syndrome respiratoire aigu sévère, Virus du SRAS.
- pharmacologie : Anticorps antiviraux.
- toxicité : Anticorps antiviraux, Fragments Fab d'immunoglobuline.
- usage thérapeutique : Anticorps antiviraux, Fragments Fab d'immunoglobuline.
- Animaux, Cellules Vero, Effet cytopathogène viral, Equus caballus, Femelle, Immunisation passive, Injections péritoneales, Modèles animaux de maladie humaine, Relation dose-effet des médicaments, Souris, Spécificité des anticorps, Syndrome respiratoire aigu sévère, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (immunology), Antibodies, Viral (pharmacology), Antibodies, Viral (therapeutic use), Antibodies, Viral (toxicity), Antibody Specificity, Chlorocebus aethiops, Cytopathogenic Effect, Viral (drug effects), Disease Models, Animal, Dose-Response Relationship, Drug, Female, Horses, Immunization, Passive, Immunoglobulin Fab Fragments (administration & dosage), Immunoglobulin Fab Fragments (immunology), Immunoglobulin Fab Fragments (therapeutic use), Immunoglobulin Fab Fragments (toxicity), Injections, Intraperitoneal, Mice, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (therapy), Vero Cells.
- MESH :
- chemical , administration & dosage : Immunoglobulin Fab Fragments.
- chemical , immunology : Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemical , pharmacology : Antibodies, Viral.
- chemical , therapeutic use : Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemical , toxicity : Antibodies, Viral, Immunoglobulin Fab Fragments.
- drug effects : Cytopathogenic Effect, Viral.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- therapy : Severe Acute Respiratory Syndrome.
- Animals, Antibody Specificity, Chlorocebus aethiops, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Horses, Immunization, Passive, Injections, Intraperitoneal, Mice, Neutralization Tests, Vero Cells.
Abstract
The aetiological agent for severe acute respiratory syndrome (SARS) has been determined to be a new type of coronavirus (SARS-CoV) that infects a wide range of mammalian hosts. Up to now, there have been no specific drugs to protect against SARS-CoV infection, thus developing effective strategies against this newly emerged viral infection warrants urgent efforts. Adoptive immune therapy with pathogen-specific heterologous immunoglobulin has been successfully used to control the dissemination of many viral infections. To investigate whether a neutralizing antibody against SARS-CoV raised in an artiodactylous host can have a protective role on primate cells, we prepared serum IgGs and their pepsin-digested F(ab')2 fragments from horses inoculated with purified SARS-CoV (BJ-01 strain). The protective effect of the F(ab')2 fragments against SARS-CoV infection was determined in cultured Vero E6 cells by cytopathic effect (CPE), MTT and plaque-forming assays and in a Balb/c mouse model by CPE and quantitative RT-PCR. The results showed the neutralization titres of F(ab')2 from three horses all reached at least 1:1600, and 50 microg of the F(ab')2 fragments could completely neutralize 1x10(4) TCID50- SARS-CoV in vivo. Additionally, we observed that F(ab')2, against BJ-01 strain could also protect cells from infection by the variant GZ-01 strain in vitro and in vivo. Our work has provided experimental support for testing the protective equine immunoglobulin in future large primate or human trials.
PubMed: 16152762
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16152762Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.</title><author><name sortKey="Wang, Xiliang" sort="Wang, Xiliang" uniqKey="Wang X" first="Xiliang" last="Wang">Xiliang Wang</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Ni, Bing" sort="Ni, Bing" uniqKey="Ni B" first="Bing" last="Ni">Bing Ni</name></author><author><name sortKey="Du, Xinan" sort="Du, Xinan" uniqKey="Du X" first="Xinan" last="Du">Xinan Du</name></author><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></author><author><name sortKey="Gao, Wenda" sort="Gao, Wenda" uniqKey="Gao W" first="Wenda" last="Gao">Wenda Gao</name></author><author><name sortKey="Shi, Xinfu" sort="Shi, Xinfu" uniqKey="Shi X" first="Xinfu" last="Shi">Xinfu Shi</name></author><author><name sortKey="Zhang, Songle" sort="Zhang, Songle" uniqKey="Zhang S" first="Songle" last="Zhang">Songle Zhang</name></author><author><name sortKey="Zhang, Liangyan" sort="Zhang, Liangyan" uniqKey="Zhang L" first="Liangyan" last="Zhang">Liangyan Zhang</name></author><author><name sortKey="Wang, Dong" sort="Wang, Dong" uniqKey="Wang D" first="Dong" last="Wang">Dong Wang</name></author><author><name sortKey="Luo, Deyan" sort="Luo, Deyan" uniqKey="Luo D" first="Deyan" last="Luo">Deyan Luo</name></author><author><name sortKey="Xing, Li" sort="Xing, Li" uniqKey="Xing L" first="Li" last="Xing">Li Xing</name></author><author><name sortKey="Jiang, Haiyan" sort="Jiang, Haiyan" uniqKey="Jiang H" first="Haiyan" last="Jiang">Haiyan Jiang</name></author><author><name sortKey="Li, Wanling" sort="Li, Wanling" uniqKey="Li W" first="Wanling" last="Li">Wanling Li</name></author><author><name sortKey="Jiang, Man" sort="Jiang, Man" uniqKey="Jiang M" first="Man" last="Jiang">Man Jiang</name></author><author><name sortKey="Mao, Liwei" sort="Mao, Liwei" uniqKey="Mao L" first="Liwei" last="Mao">Liwei Mao</name></author><author><name sortKey="He, Yangdong" sort="He, Yangdong" uniqKey="He Y" first="Yangdong" last="He">Yangdong He</name></author><author><name sortKey="Xiao, Yu" sort="Xiao, Yu" uniqKey="Xiao Y" first="Yu" last="Xiao">Yu Xiao</name></author><author><name sortKey="Wu, Yuzhang" sort="Wu, Yuzhang" uniqKey="Wu Y" first="Yuzhang" last="Wu">Yuzhang Wu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16152762</idno><idno type="pmid">16152762</idno><idno type="wicri:Area/PubMed/Corpus">002551</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002551</idno><idno type="wicri:Area/PubMed/Curation">002551</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002551</idno><idno type="wicri:Area/PubMed/Checkpoint">002566</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002566</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.</title><author><name sortKey="Wang, Xiliang" sort="Wang, Xiliang" uniqKey="Wang X" first="Xiliang" last="Wang">Xiliang Wang</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Ni, Bing" sort="Ni, Bing" uniqKey="Ni B" first="Bing" last="Ni">Bing Ni</name></author><author><name sortKey="Du, Xinan" sort="Du, Xinan" uniqKey="Du X" first="Xinan" last="Du">Xinan Du</name></author><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></author><author><name sortKey="Gao, Wenda" sort="Gao, Wenda" uniqKey="Gao W" first="Wenda" last="Gao">Wenda Gao</name></author><author><name sortKey="Shi, Xinfu" sort="Shi, Xinfu" uniqKey="Shi X" first="Xinfu" last="Shi">Xinfu Shi</name></author><author><name sortKey="Zhang, Songle" sort="Zhang, Songle" uniqKey="Zhang S" first="Songle" last="Zhang">Songle Zhang</name></author><author><name sortKey="Zhang, Liangyan" sort="Zhang, Liangyan" uniqKey="Zhang L" first="Liangyan" last="Zhang">Liangyan Zhang</name></author><author><name sortKey="Wang, Dong" sort="Wang, Dong" uniqKey="Wang D" first="Dong" last="Wang">Dong Wang</name></author><author><name sortKey="Luo, Deyan" sort="Luo, Deyan" uniqKey="Luo D" first="Deyan" last="Luo">Deyan Luo</name></author><author><name sortKey="Xing, Li" sort="Xing, Li" uniqKey="Xing L" first="Li" last="Xing">Li Xing</name></author><author><name sortKey="Jiang, Haiyan" sort="Jiang, Haiyan" uniqKey="Jiang H" first="Haiyan" last="Jiang">Haiyan Jiang</name></author><author><name sortKey="Li, Wanling" sort="Li, Wanling" uniqKey="Li W" first="Wanling" last="Li">Wanling Li</name></author><author><name sortKey="Jiang, Man" sort="Jiang, Man" uniqKey="Jiang M" first="Man" last="Jiang">Man Jiang</name></author><author><name sortKey="Mao, Liwei" sort="Mao, Liwei" uniqKey="Mao L" first="Liwei" last="Mao">Liwei Mao</name></author><author><name sortKey="He, Yangdong" sort="He, Yangdong" uniqKey="He Y" first="Yangdong" last="He">Yangdong He</name></author><author><name sortKey="Xiao, Yu" sort="Xiao, Yu" uniqKey="Xiao Y" first="Yu" last="Xiao">Yu Xiao</name></author><author><name sortKey="Wu, Yuzhang" sort="Wu, Yuzhang" uniqKey="Wu Y" first="Yuzhang" last="Wu">Yuzhang Wu</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Antibodies, Viral (pharmacology)</term><term>Antibodies, Viral (therapeutic use)</term><term>Antibodies, Viral (toxicity)</term><term>Antibody Specificity</term><term>Chlorocebus aethiops</term><term>Cytopathogenic Effect, Viral (drug effects)</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Horses</term><term>Immunization, Passive</term><term>Immunoglobulin Fab Fragments (administration & dosage)</term><term>Immunoglobulin Fab Fragments (immunology)</term><term>Immunoglobulin Fab Fragments (therapeutic use)</term><term>Immunoglobulin Fab Fragments (toxicity)</term><term>Injections, Intraperitoneal</term><term>Mice</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Vero Cells</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (pharmacologie)</term><term>Anticorps antiviraux (toxicité)</term><term>Anticorps antiviraux (usage thérapeutique)</term><term>Cellules Vero</term><term>Effet cytopathogène viral ()</term><term>Equus caballus</term><term>Femelle</term><term>Fragments Fab d'immunoglobuline (administration et posologie)</term><term>Fragments Fab d'immunoglobuline (immunologie)</term><term>Fragments Fab d'immunoglobuline (toxicité)</term><term>Fragments Fab d'immunoglobuline (usage thérapeutique)</term><term>Immunisation passive</term><term>Injections péritoneales</term><term>Modèles animaux de maladie humaine</term><term>Relation dose-effet des médicaments</term><term>Souris</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunoglobulin Fab Fragments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin Fab Fragments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin Fab Fragments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin Fab Fragments</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Fragments Fab d'immunoglobuline</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Fragments Fab d'immunoglobuline</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="toxicité" xml:lang="fr"><term>Anticorps antiviraux</term><term>Fragments Fab d'immunoglobuline</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps antiviraux</term><term>Fragments Fab d'immunoglobuline</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Specificity</term><term>Chlorocebus aethiops</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Horses</term><term>Immunization, Passive</term><term>Injections, Intraperitoneal</term><term>Mice</term><term>Neutralization Tests</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Effet cytopathogène viral</term><term>Equus caballus</term><term>Femelle</term><term>Immunisation passive</term><term>Injections péritoneales</term><term>Modèles animaux de maladie humaine</term><term>Relation dose-effet des médicaments</term><term>Souris</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aetiological agent for severe acute respiratory syndrome (SARS) has been determined to be a new type of coronavirus (SARS-CoV) that infects a wide range of mammalian hosts. Up to now, there have been no specific drugs to protect against SARS-CoV infection, thus developing effective strategies against this newly emerged viral infection warrants urgent efforts. Adoptive immune therapy with pathogen-specific heterologous immunoglobulin has been successfully used to control the dissemination of many viral infections. To investigate whether a neutralizing antibody against SARS-CoV raised in an artiodactylous host can have a protective role on primate cells, we prepared serum IgGs and their pepsin-digested F(ab')2 fragments from horses inoculated with purified SARS-CoV (BJ-01 strain). The protective effect of the F(ab')2 fragments against SARS-CoV infection was determined in cultured Vero E6 cells by cytopathic effect (CPE), MTT and plaque-forming assays and in a Balb/c mouse model by CPE and quantitative RT-PCR. The results showed the neutralization titres of F(ab')2 from three horses all reached at least 1:1600, and 50 microg of the F(ab')2 fragments could completely neutralize 1x10(4) TCID50- SARS-CoV in vivo. Additionally, we observed that F(ab')2, against BJ-01 strain could also protect cells from infection by the variant GZ-01 strain in vitro and in vivo. Our work has provided experimental support for testing the protective equine immunoglobulin in future large primate or human trials.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16152762</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-6535</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.</ArticleTitle><Pagination><MedlinePgn>681-90</MedlinePgn></Pagination><Abstract><AbstractText>The aetiological agent for severe acute respiratory syndrome (SARS) has been determined to be a new type of coronavirus (SARS-CoV) that infects a wide range of mammalian hosts. Up to now, there have been no specific drugs to protect against SARS-CoV infection, thus developing effective strategies against this newly emerged viral infection warrants urgent efforts. Adoptive immune therapy with pathogen-specific heterologous immunoglobulin has been successfully used to control the dissemination of many viral infections. To investigate whether a neutralizing antibody against SARS-CoV raised in an artiodactylous host can have a protective role on primate cells, we prepared serum IgGs and their pepsin-digested F(ab')2 fragments from horses inoculated with purified SARS-CoV (BJ-01 strain). The protective effect of the F(ab')2 fragments against SARS-CoV infection was determined in cultured Vero E6 cells by cytopathic effect (CPE), MTT and plaque-forming assays and in a Balb/c mouse model by CPE and quantitative RT-PCR. The results showed the neutralization titres of F(ab')2 from three horses all reached at least 1:1600, and 50 microg of the F(ab')2 fragments could completely neutralize 1x10(4) TCID50- SARS-CoV in vivo. Additionally, we observed that F(ab')2, against BJ-01 strain could also protect cells from infection by the variant GZ-01 strain in vitro and in vivo. Our work has provided experimental support for testing the protective equine immunoglobulin in future large primate or human trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Bing</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Xinan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guangyu</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wenda</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xinfu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Songle</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liangyan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Deyan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wanling</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Man</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Liwei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yangdong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuzhang</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006736" MajorTopicYN="N">Horses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007140" MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="Y">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16152762</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><settlement><li>Pékin</li></settlement></list><tree><noCountry><name sortKey="Du, Xinan" sort="Du, Xinan" uniqKey="Du X" first="Xinan" last="Du">Xinan Du</name><name sortKey="Gao, Wenda" sort="Gao, Wenda" uniqKey="Gao W" first="Wenda" last="Gao">Wenda Gao</name><name sortKey="He, Yangdong" sort="He, Yangdong" uniqKey="He Y" first="Yangdong" last="He">Yangdong He</name><name sortKey="Jiang, Haiyan" sort="Jiang, Haiyan" uniqKey="Jiang H" first="Haiyan" last="Jiang">Haiyan Jiang</name><name sortKey="Jiang, Man" sort="Jiang, Man" uniqKey="Jiang M" first="Man" last="Jiang">Man Jiang</name><name sortKey="Li, Wanling" sort="Li, Wanling" uniqKey="Li W" first="Wanling" last="Li">Wanling Li</name><name sortKey="Luo, Deyan" sort="Luo, Deyan" uniqKey="Luo D" first="Deyan" last="Luo">Deyan Luo</name><name sortKey="Mao, Liwei" sort="Mao, Liwei" uniqKey="Mao L" first="Liwei" last="Mao">Liwei Mao</name><name sortKey="Ni, Bing" sort="Ni, Bing" uniqKey="Ni B" first="Bing" last="Ni">Bing Ni</name><name sortKey="Shi, Xinfu" sort="Shi, Xinfu" uniqKey="Shi X" first="Xinfu" last="Shi">Xinfu Shi</name><name sortKey="Wang, Dong" sort="Wang, Dong" uniqKey="Wang D" first="Dong" last="Wang">Dong Wang</name><name sortKey="Wu, Yuzhang" sort="Wu, Yuzhang" uniqKey="Wu Y" first="Yuzhang" last="Wu">Yuzhang Wu</name><name sortKey="Xiao, Yu" sort="Xiao, Yu" uniqKey="Xiao Y" first="Yu" last="Xiao">Yu Xiao</name><name sortKey="Xing, Li" sort="Xing, Li" uniqKey="Xing L" first="Li" last="Xing">Li Xing</name><name sortKey="Zhang, Liangyan" sort="Zhang, Liangyan" uniqKey="Zhang L" first="Liangyan" last="Zhang">Liangyan Zhang</name><name sortKey="Zhang, Songle" sort="Zhang, Songle" uniqKey="Zhang S" first="Songle" last="Zhang">Songle Zhang</name><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Wang, Xiliang" sort="Wang, Xiliang" uniqKey="Wang X" first="Xiliang" last="Wang">Xiliang Wang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002566 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002566 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16152762
|texte= Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16152762" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |